vs
Side-by-side financial comparison of Citius Pharmaceuticals, Inc. (CTXR) and Marathon Bancorp, Inc. (MBBC). Click either name above to swap in a different company.
Citius Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($3.9M vs $2.2M, roughly 1.8× Marathon Bancorp, Inc.). Marathon Bancorp, Inc. runs the higher net margin — 22.3% vs -238.2%, a 260.5% gap on every dollar of revenue.
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies addressing unmet medical needs across critical care, oncology, anti-infective treatment, and supportive care segments, primarily serving the U.S. healthcare market.
Marathon Bancorp, Inc. is a Maryland-based financial holding company that primarily operates through its community bank subsidiary. It offers a full range of retail and commercial banking products including deposit accounts, consumer loans, commercial mortgages, and small business financing, serving individual and small-to-medium enterprise customers across local markets in Maryland.
CTXR vs MBBC — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $2.2M |
| Net Profit | $-9.4M | $501.4K |
| Gross Margin | 80.0% | — |
| Operating Margin | -228.7% | 26.2% |
| Net Margin | -238.2% | 22.3% |
| Revenue YoY | — | 41.7% |
| Net Profit YoY | 8.6% | 880.7% |
| EPS (diluted) | $-0.38 | $0.19 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | $2.2M | ||
| Q3 25 | — | $2.1M | ||
| Q2 25 | — | $1.9M | ||
| Q1 25 | — | $1.7M | ||
| Q4 24 | — | $1.6M | ||
| Q3 24 | — | $1.6M | ||
| Q2 24 | — | $1.6M | ||
| Q1 24 | — | $1.6M |
| Q4 25 | $-9.4M | $501.4K | ||
| Q3 25 | — | $444.3K | ||
| Q2 25 | — | $-332.0K | ||
| Q1 25 | — | $148.4K | ||
| Q4 24 | — | $51.1K | ||
| Q3 24 | — | $174.9K | ||
| Q2 24 | — | $85.8K | ||
| Q1 24 | — | $-631.1K |
| Q4 25 | 80.0% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -228.7% | 26.2% | ||
| Q3 25 | — | 25.5% | ||
| Q2 25 | — | -25.7% | ||
| Q1 25 | — | 11.6% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | — | 13.4% | ||
| Q2 24 | — | 4.1% | ||
| Q1 24 | — | -53.7% |
| Q4 25 | -238.2% | 22.3% | ||
| Q3 25 | — | 20.7% | ||
| Q2 25 | — | -18.9% | ||
| Q1 25 | — | 8.9% | ||
| Q4 24 | — | 3.2% | ||
| Q3 24 | — | 10.8% | ||
| Q2 24 | — | 6.2% | ||
| Q1 24 | — | -40.7% |
| Q4 25 | $-0.38 | $0.19 | ||
| Q3 25 | — | $0.17 | ||
| Q2 25 | — | $-0.13 | ||
| Q1 25 | — | $0.07 | ||
| Q4 24 | — | $0.02 | ||
| Q3 24 | — | $0.06 | ||
| Q2 24 | — | $0.07 | ||
| Q1 24 | — | $-0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.7M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $80.0M | $46.9M |
| Total Assets | $140.4M | $248.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.7M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $80.0M | $46.9M | ||
| Q3 25 | — | $46.3M | ||
| Q2 25 | — | $45.7M | ||
| Q1 25 | — | $32.0M | ||
| Q4 24 | — | $31.7M | ||
| Q3 24 | — | $31.6M | ||
| Q2 24 | — | $31.3M | ||
| Q1 24 | — | $31.4M |
| Q4 25 | $140.4M | $248.0M | ||
| Q3 25 | — | $246.0M | ||
| Q2 25 | — | $238.8M | ||
| Q1 25 | — | $236.8M | ||
| Q4 24 | — | $217.9M | ||
| Q3 24 | — | $216.5M | ||
| Q2 24 | — | $219.3M | ||
| Q1 24 | — | $225.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-13.0M | $1.4M |
| Free Cash FlowOCF − Capex | — | $1.4M |
| FCF MarginFCF / Revenue | — | 62.3% |
| Capex IntensityCapex / Revenue | — | 0.6% |
| Cash ConversionOCF / Net Profit | — | 2.82× |
| TTM Free Cash FlowTrailing 4 quarters | — | $3.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-13.0M | $1.4M | ||
| Q3 25 | — | $464.0K | ||
| Q2 25 | — | $1.4M | ||
| Q1 25 | — | $849.0K | ||
| Q4 24 | — | $113.6K | ||
| Q3 24 | — | $945.2K | ||
| Q2 24 | — | $416.6K | ||
| Q1 24 | — | $-802.1K |
| Q4 25 | — | $1.4M | ||
| Q3 25 | — | $456.6K | ||
| Q2 25 | — | $1.3M | ||
| Q1 25 | — | $773.2K | ||
| Q4 24 | — | $105.0K | ||
| Q3 24 | — | $921.6K | ||
| Q2 24 | — | $-1.8M | ||
| Q1 24 | — | $-1.1M |
| Q4 25 | — | 62.3% | ||
| Q3 25 | — | 21.3% | ||
| Q2 25 | — | 66.0% | ||
| Q1 25 | — | 46.3% | ||
| Q4 24 | — | 6.6% | ||
| Q3 24 | — | 57.1% | ||
| Q2 24 | — | -118.5% | ||
| Q1 24 | — | -67.9% |
| Q4 25 | — | 0.6% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | — | 9.3% | ||
| Q1 25 | — | 4.5% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | 145.2% | ||
| Q1 24 | — | 16.2% |
| Q4 25 | — | 2.82× | ||
| Q3 25 | — | 1.04× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.72× | ||
| Q4 24 | — | 2.22× | ||
| Q3 24 | — | 5.40× | ||
| Q2 24 | — | 4.85× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
